Clinical Practice Guidelines6 Reference Pages
Section 1 of 5 • Diagnostics

Clinical Practice Guidelines for Patient Identification

How global hepatology, diabetes, endocrinology, cardiology, pediatric, and radiology societies align on identifying MASLD/MASH and selecting therapy without routine biopsy.

What This Means for Patients

One of our biggest challenges in liver disease has been that primary care doctors rarely screened for silent liver scarring until problems showed up late. That standard has finally changed: liver, diabetes, heart, and endocrine societies now agree that anyone with type 2 diabetes, obesity with metabolic risk factors, or persistent elevated liver enzymes needs proactive fibrosis screening — and AASLD now defines exact noninvasive cutoffs so eligible F2–F3 MASH patients can start approved treatments without a needle biopsy.

Visualizes progression from simple steatosis (MASLD) to MASH and F4 cirrhosis, plus US standard drink math (14 g), MetALD zones, PEth blood testing, and an interactive drink calculator.

Synthesizes consensus recommendations across AASLD, AGA, AACE, ADA 2026, and EASL-EASD-EASO on first-line FIB-4 screening and second-line ELF or VCTE testing.

Step-by-step AASLD 2023 diagnostic algorithm spanning Primary Care, Either Care Setting (VCTE and ELF risk tiers), and GI/Hepatology specialist management.

Updated ADA 2026 Section 4 clinical algorithm designed to prevent cirrhosis in people with type 2 diabetes, prediabetes, or obesity with cardiovascular risk factors.

Side-by-side comparison of 12 specialty and international guidelines: EASL-EASD-EASO 2024, AASLD NILDA 2025, AACE, AGA Lean MASLD, AHA statin safety, NASPGHAN pediatrics, SRU, and APASL.

AASLD 2024–2025 biopsy-free NIT thresholds (VCTE 8–15 kPa, MRE 3.1–4.4 kPa, ELF 9.2–10.5) for MASH pharmacotherapy plus 6–12 month positive treatment-response benchmarks.